CD70 and nonpapillary renal cell carcinoma: A notable trial among these is TRAVERSE (NCT04696731), which is evaluating the allogeneic CD70-targeted CAR T-cell therapy, ALLO-316, in metastatic ccRCC patients refractory to both checkpoint inhibitors and TKIs [93,94].